ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma

BACKGROUND: Survivin is an anti-apoptotic protein that is highly expressed in glioblastoma (GBM). We conducted a single-arm, multi-center phase II trial in newly diagnosed GBM (nGBM) to determine 6-month progression-free survival (PFS-6), 12-month overall survival (OS-12) and immunologic response in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ahluwalia, Manmeet, Reardon, David, Abad, Ajay, Curry, William, Wong, Eric, Peereboom, David, Belal, Ahmed, Qiu, Jingxin, Mogensen, Kathleen, Schilero, Cathy, Casucci, Danielle, Mechtler, Laszlo, Uhlmann, Erik, Ciesielski, Michael, Fenstermaker, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216152/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.036
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados